Optimizing Urological Concurrent Robotic Multisite Surgery: Juxtaposing a Single-Center Experience and a Literature Review.

IF 3 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Journal of Personalized Medicine Pub Date : 2024-10-11 DOI:10.3390/jpm14101053
Rafał B Drobot, Marcin Lipa, Weronika A Zahorska, Daniel Ludwiczak, Artur A Antoniewicz
{"title":"Optimizing Urological Concurrent Robotic Multisite Surgery: Juxtaposing a Single-Center Experience and a Literature Review.","authors":"Rafał B Drobot, Marcin Lipa, Weronika A Zahorska, Daniel Ludwiczak, Artur A Antoniewicz","doi":"10.3390/jpm14101053","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction</b>: This article juxtaposes case series with a systematic review to evaluate the feasibility, safety, and clinical outcomes of concurrent robotic multisite urological surgeries, specifically robot-assisted radical prostatectomy (RARP) and robot-assisted partial nephrectomy (RAPN), for synchronous prostate and kidney cancers. <b>Aim</b>: The aims of this study were to evaluate the feasibility, safety, and clinical outcomes of urological concurrent robotic multisite surgeries through a comparison of institutional findings with the existing literature. <b>Materials and Methods</b>: A retrospective analysis was conducted on eight institutional cases of concurrent robotic multisite surgeries performed between 2021 and 2024. The primary outcomes measured were operative time, blood loss, and postoperative complications. A systematic review of the literature was performed, searching PubMed, Embase, and Cochrane Library databases, with the last search conducted on 1 July 2024. Studies were included if they reported on concurrent robotic surgeries corresponding to the procedures performed at the institution, including RARP with RAPN, RARP with robotic transabdominal preperitoneal inguinal hernia repair (RTAPPIHR), and other multisite robotic surgeries. Risk of bias was assessed using the modified Newcastle-Ottawa Scale. Descriptive statistics were used to analyze operative time and blood loss, with confidence intervals (CIs) calculated to assess precision. Categorical variables, including postoperative complications, were summarized using frequencies and percentages. Heterogeneity was assessed using the I<sup>2</sup> statistic, with values above 50% indicating substantial heterogeneity. A random effects model was applied when necessary, and sensitivity analyses excluded studies with high risk of bias. <b>Results</b>: We describe a unique docking technique employed in our procedures, which allows for atraumatic transitions between surgeries using the same port sites. Our institutional cases demonstrated the feasibility and safety of concurrent robotic multisite surgery, with a mean operative time of 315 min (95% CI: 290-340) and mean blood loss of 300 mL (95% CI: 250-350). There were no significant intraoperative complications reported. These findings are consistent with the literature, where mean operative times range from 390 to 430 min and blood loss ranges from 200 to 330 mL. Notably, no positive surgical margins or declines in postoperative renal function were observed in our cases. The systematic review included nine retrospective studies involving 40 cases of concurrent RARP and RAPN, as well as eleven studies including 392 cases of RARP combined with RTAPPIHR. The findings from these studies support the feasibility and safety of concurrent surgeries, showing similar rates of operative time, blood loss, and postoperative complications. <b>Conclusions:</b> Concurrent robotic multisite surgeries, such as RARP combined with RAPN or RTAPPIHR, appear to be safe and feasible. Our data suggest these procedures are non-inferior to separate surgeries in terms of safety and complication rates. Potential benefits, including reduced operative times, shorter hospital stays, and more efficient resource use, may translate into cost savings, although no formal cost-effectiveness analysis was conducted. Limitations include the small sample size, retrospective design, and lack of long-term follow-up. Prospective trials are needed to validate these findings and further refine the techniques. <b>Funding:</b> this review did not receive any external funding. <b>Registration:</b> this review was not registered in any public protocol registry due to its comparative retrospective nature.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"14 10","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11509092/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm14101053","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: This article juxtaposes case series with a systematic review to evaluate the feasibility, safety, and clinical outcomes of concurrent robotic multisite urological surgeries, specifically robot-assisted radical prostatectomy (RARP) and robot-assisted partial nephrectomy (RAPN), for synchronous prostate and kidney cancers. Aim: The aims of this study were to evaluate the feasibility, safety, and clinical outcomes of urological concurrent robotic multisite surgeries through a comparison of institutional findings with the existing literature. Materials and Methods: A retrospective analysis was conducted on eight institutional cases of concurrent robotic multisite surgeries performed between 2021 and 2024. The primary outcomes measured were operative time, blood loss, and postoperative complications. A systematic review of the literature was performed, searching PubMed, Embase, and Cochrane Library databases, with the last search conducted on 1 July 2024. Studies were included if they reported on concurrent robotic surgeries corresponding to the procedures performed at the institution, including RARP with RAPN, RARP with robotic transabdominal preperitoneal inguinal hernia repair (RTAPPIHR), and other multisite robotic surgeries. Risk of bias was assessed using the modified Newcastle-Ottawa Scale. Descriptive statistics were used to analyze operative time and blood loss, with confidence intervals (CIs) calculated to assess precision. Categorical variables, including postoperative complications, were summarized using frequencies and percentages. Heterogeneity was assessed using the I2 statistic, with values above 50% indicating substantial heterogeneity. A random effects model was applied when necessary, and sensitivity analyses excluded studies with high risk of bias. Results: We describe a unique docking technique employed in our procedures, which allows for atraumatic transitions between surgeries using the same port sites. Our institutional cases demonstrated the feasibility and safety of concurrent robotic multisite surgery, with a mean operative time of 315 min (95% CI: 290-340) and mean blood loss of 300 mL (95% CI: 250-350). There were no significant intraoperative complications reported. These findings are consistent with the literature, where mean operative times range from 390 to 430 min and blood loss ranges from 200 to 330 mL. Notably, no positive surgical margins or declines in postoperative renal function were observed in our cases. The systematic review included nine retrospective studies involving 40 cases of concurrent RARP and RAPN, as well as eleven studies including 392 cases of RARP combined with RTAPPIHR. The findings from these studies support the feasibility and safety of concurrent surgeries, showing similar rates of operative time, blood loss, and postoperative complications. Conclusions: Concurrent robotic multisite surgeries, such as RARP combined with RAPN or RTAPPIHR, appear to be safe and feasible. Our data suggest these procedures are non-inferior to separate surgeries in terms of safety and complication rates. Potential benefits, including reduced operative times, shorter hospital stays, and more efficient resource use, may translate into cost savings, although no formal cost-effectiveness analysis was conducted. Limitations include the small sample size, retrospective design, and lack of long-term follow-up. Prospective trials are needed to validate these findings and further refine the techniques. Funding: this review did not receive any external funding. Registration: this review was not registered in any public protocol registry due to its comparative retrospective nature.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
优化泌尿外科并发机器人多部位手术:单中心经验与文献综述并列。
导言:本文将病例系列与系统综述并列,以评估多部位泌尿外科同步机器人手术的可行性、安全性和临床结果,特别是机器人辅助根治性前列腺切除术(RARP)和机器人辅助肾部分切除术(RAPN)治疗同步前列腺癌和肾癌。目的:本研究的目的是通过将机构研究结果与现有文献进行比较,评估泌尿外科同步机器人多部位手术的可行性、安全性和临床结果。材料与方法:我们对 2021 年至 2024 年间进行的 8 例多点同步机器人手术进行了回顾性分析。测量的主要结果是手术时间、失血量和术后并发症。通过检索PubMed、Embase和Cochrane图书馆数据库,对文献进行了系统性回顾,最后一次检索于2024年7月1日进行。如果研究报告的同期机器人手术与该机构进行的手术相符,包括RARP与RAPN、RARP与机器人经腹腹膜前腹股沟疝修补术(RTAPPIHR)以及其他多部位机器人手术,则纳入该研究。偏倚风险采用改良的纽卡斯尔-渥太华量表进行评估。描述性统计用于分析手术时间和失血量,并计算置信区间(CI)以评估精确度。分类变量(包括术后并发症)采用频率和百分比进行总结。异质性采用I2统计量进行评估,其值超过50%表示异质性很大。必要时采用随机效应模型,敏感性分析排除了偏倚风险较高的研究。研究结果我们介绍了在手术中采用的一种独特的对接技术,该技术允许使用相同的端口部位进行无创伤的手术转换。我们的机构病例证明了机器人多部位同时手术的可行性和安全性,平均手术时间为 315 分钟(95% CI:290-340),平均失血量为 300 毫升(95% CI:250-350)。无重大术中并发症报告。这些结果与文献报道一致,文献报道的平均手术时间为 390 至 430 分钟,平均失血量为 200 至 330 毫升。值得注意的是,在我们的病例中没有观察到手术切缘阳性或术后肾功能下降的情况。系统性综述包括九项回顾性研究,涉及 40 例同时进行 RARP 和 RAPN 的病例,以及十一项研究,包括 392 例 RARP 联合 RTAPPIHR 的病例。这些研究结果支持同期手术的可行性和安全性,显示手术时间、失血量和术后并发症的发生率相似。结论并发机器人多部位手术,如RARP联合RAPN或RTAPPIHR,似乎是安全可行的。我们的数据表明,就安全性和并发症发生率而言,这些手术并不比单独手术差。尽管没有进行正式的成本效益分析,但包括缩短手术时间、缩短住院时间和提高资源利用效率在内的潜在优势可能会节省成本。不足之处包括样本量小、回顾性设计以及缺乏长期随访。需要进行前瞻性试验来验证这些研究结果,并进一步完善相关技术。经费:本研究未获得任何外部资助。注册:由于其比较性回顾性质,本综述未在任何公共协议注册处注册。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Personalized Medicine
Journal of Personalized Medicine Medicine-Medicine (miscellaneous)
CiteScore
4.10
自引率
0.00%
发文量
1878
审稿时长
11 weeks
期刊介绍: Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.
期刊最新文献
Electrophysiologic Considerations in Adult Patients with Ebstein's Anomaly. Exploring the Structural and Functional Consequences of Deleterious Missense Nonsynonymous SNPs in the EPOR Gene: A Computational Approach. The Effects of Mepolizumab on CRSwNP: Real-Life Evidence. Clinical Implication of Brain Metastases En-Bloc Resection: Surgical Technique Description and Literature Review. Limits in the Perception of Facial Symmetry-A Prospective Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1